King, Jenny
Institute of Cancer Research
2 papers on CoChat
Most cited papers
- Verified
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology
Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling
Cited by 78
- Verified
Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., et al. (2021) · Cancer Research
Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways
Cited by 10
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free